Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Oncology

• Publication date

  2017-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/annonc/mdx183PMID 28407039
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis

  2017cited by this paper
• Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

  2017cited by this paper
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

  2017cited by this paper
• Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

  2016cited by this paper
• Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Evolving synergistic combinations of targeted immunotherapies to combat cancer

  2015cited by this paper
• The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

  2015cited by this paper
• Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression*

  2015cited by this paper
• Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression

  2014cited by this paper
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper

• Immunotherapy after EGFR-TKI treatment in advanced non-small cell lung cancer: Current status and future perspectives (Review)

  2026cites this paper
• Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis.

  2026cites this paper
• Restoring osimertinib sensitivity in EGFR-mutant NSCLC: the role of anlotinib in modulating Wnt/β-catenin/YAP pathways.

  2026cites this paper
• Survival Outcomes in EGFR‐Mutant Non‐Small Cell Lung Cancer With Brain Metastases: Kaplan–Meier and Cox Regression Analyses Across Treatment Stages

  2025cites this paper
• Characteristics of Epidermal Growth Factor Receptor-Mutant Nonsmall-Cell Lung Cancer Patients Benefiting From Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Efficacy and safety of furmonertinib in patients with EGFR‑mutant advanced lung adenocarcinoma after failure of multiple lines of therapy: A single‑center retrospective study

  2025influential citation
• Distinct survival, optimal combination strategy of immunotherapy, and immunophenotype in uncommon and 20ins EGFR-mut lung adenocarcinoma: a multi-center study

  2025cites this paper
• Comparative predictive value of immunotherapy biomarkers: a systematic review and network meta-analysis.

  2025cites this paper
• Shaping the battlefield: EGFR and KRAS tumor mutations’ role on the immune microenvironment and immunotherapy responses in lung cancer

  2025cites this paper
• Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance

  2025cites this paper
• Radiomic features and tumor immune microenvironment associated with anaplastic lymphoma kinase-rearranged lung adenocarcinoma and their prognostic value

  2025cites this paper
• Localization of epidermal growth factor receptor-mutations using PNA:DNA probes in clinical specimens from patients with non-small cell lung cancer

  2025cites this paper
• Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Chemotherapy-Naïve Advanced Non–Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized Trials

  2025cites this paper
• Drug resistance in cancer: molecular mechanisms and emerging treatment strategies

  2025cites this paper
• Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission to anti PD-1 antibody

  2025cites this paper
• The role of immunotherapy and chemotherapy combinations in TKI-resistant EGFR-mutant non-small cell lung cancer: insights from real-world evidence.

  2025cites this paper
• A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus on non-small cell lung cancer

  2025influential citation
• Antibody-drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC: a Bayesian network meta-analysis

  2025cites this paper
• Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns.

  2025cites this paper
• Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world

  2025cites this paper
• The role of EGFR mutations in sensitivity of PD-1/PD-L1 blockade in non-small cell lung cancer.

  2025cites this paper
• EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy

  2025cites this paper
• Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis.

  2025cites this paper
• Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy

  2025cites this paper
• Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review

  2024cites this paper
• Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure

  2024cites this paper
• Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen.

  2024cites this paper
• Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy

  2024cites this paper
• Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits.

  2024cites this paper
• PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer

  2024cites this paper
• The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial

  2024cites this paper
• The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations

  2024cites this paper
• Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade

  2024cites this paper
• Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma

  2024cites this paper
• The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study

  2024cites this paper
• PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy

  2024cites this paper
• Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC

  2024cites this paper
• Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance

  2024cites this paper
• Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.

  2024cites this paper
• Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy

  2024cites this paper
• Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis

  2024cites this paper
• Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer

  2024cites this paper
• Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

  2024cites this paper
• Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired EGFR 19Del/T790M/cis-C797S mutation resistance

  2024cites this paper
• Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.

  2024cites this paper
• COL5A2-Dependent Cancer-associated Fibroblasts (CAF) Reveals Regulation of the Tumor Microenvironment and Response to Immunotherapy in Lung Adenocarcinoma

  2023cites this paper
• Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment

  2023cites this paper
• Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations

  2023cites this paper
• Molecular Diagnostics of Oncological Disease: Prospects for the Development of a Reference Material for the HER2 gene Content

  2023cites this paper
• Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.

  2023cites this paper
• Bone marrow adipocytes induce cancer‐associated fibroblasts and immune evasion, enhancing invasion and drug resistance

  2023cites this paper
• Anti-PD-(L)1 therapy of non-small cell lung cancer–A summary of clinical trials and current progresses

  2023cites this paper
• Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

  2023cites this paper
• Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor‑infiltrating CD68‑positive cell counts in patients with EGFR‑mutant non‑small cell lung cancer

  2023influential citation
• Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy

  2023influential citation
• Tumor microenvironment landscape of non-small cell lung cancer reveals resistance mechanisms for PD-L1 blockade following chemoradiotherapy: a multi-center prospective biomarker study (WJOG11518L/SUBMARINE).

  2023cites this paper
• At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC

  2023cites this paper
• Ferroptosis-related STEAP3 acts as predictor and regulator in diffuse large B cell lymphoma through immune infiltration

  2023cites this paper
• Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial

  2023cites this paper
• Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients

  2023cites this paper
• A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients

  2023cites this paper
• Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance

  2023cites this paper
• Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?

  2023cites this paper
• A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).

  2023cites this paper
• The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies

  2023cites this paper
• The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study

  2023cites this paper
• EGFR-Driven Mutation in Non-Small-Cell Lung Cancer (NSCLC) Influences the Features and Outcome of Brain Metastases

  2023cites this paper
• 免疫治疗在EGFR突变晚期非小细胞肺癌中的研究进展

  2023influential citation
• Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance

  2023cites this paper
• Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies

  2023cites this paper
• Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non-small cell lung cancer

  2022cites this paper
• Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features

  2022cites this paper
• EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

  2022cites this paper
• 驱动基因阳性非小细胞肺癌免疫治疗进展

  2022cites this paper
• Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

  2022cites this paper
• Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non‐small‐cell lung cancer

  2022cites this paper
• Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers

  2022cites this paper
• Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer

  2022cites this paper
• Identification of tumor microenvironment‐based genes associated with acquired resistance to EGFR Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

  2022cites this paper
• Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC.

  2022cites this paper
• Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges

  2022cites this paper
• Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model

  2022cites this paper
• Anlotinib plus chemotherapy for T790M‐negative EGFR ‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial

  2022cites this paper
• Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review

  2022cites this paper
• Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations

  2022cites this paper
• Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients.

  2022cites this paper
• 晚期非小细胞肺癌MET扩增介导获得性耐药的研究进展

  2022cites this paper
• Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: A systematic review

  2022cites this paper
• EGFR突变NSCLC患者TKIs耐药后ICIs治疗进展

  2022cites this paper
• Role of exosomes in lung cancer: A comprehensive insight from immunomodulation to theragnostic applications.

  2022cites this paper
• Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation

  2022cites this paper
• Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors

  2022cites this paper
• A Machine Learning-Based Predictive Model of Epidermal Growth Factor Mutations in Lung Adenocarcinomas

  2022cites this paper
• Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [18F]FDG PET/CT imaging: quantitative analysis of [18F]FDG uptake in primary tumors and metastatic lymph nodes

  2022cites this paper
• Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma

  2022cites this paper
• Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells

  2022influential citation
• A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors

  2022cites this paper
• Emerging strategies to overcome resistance to third-generation EGFR inhibitors

  2022cites this paper
• Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report

  2022cites this paper
• Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.

  2022cites this paper